Spero Therapeutics (SPRO) Asset Writedowns and Impairment (2023 - 2025)
Spero Therapeutics' (SPRO) quarterly Asset Writedowns and Impairment came in at $600000.0 in Q3 2025, down 88.69% on a QoQ basis from $5.3 million in Q3 2023.
Spero Therapeutics (SPRO) Asset Writedowns and Impairment (2023 - 2025) Analysis & Trends
Spero Therapeutics (SPRO) has 2 years of Asset Writedowns and Impairment data on file, last reported at $600000.0 in Q3 2025.
- Quarterly Asset Writedowns and Impairment changed N/A year-over-year to $600000.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $600000.0 (down 88.69% YoY) and the FY2025 annual result came in at $587000.0, changed N/A from the prior year.
- Asset Writedowns and Impairment declined to $600000.0 in Q3 2025, from $5.3 million in the prior quarter.
- In the past five years, Asset Writedowns and Impairment ranged from a high of $5.3 million in Q3 2023 to a low of $600000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Spero Therapeutics | 70.72 Mn | 19.95 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 600,000.00 |
| Sep 30, 2025 | 600,000.00 |
| Sep 30, 2023 | 5.31 Mn |
| Sep 30, 2023 | 5.31 Mn |